Anzeige
Mehr »
Freitag, 20.03.2026 - Börsentäglich über 12.000 News
Während Kupfer zum Engpass wird, startet diese Aktie in Nevada die nächste große Explorationsphase
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 920657 | ISIN: FR0000120578 | Ticker-Symbol: SNW
Tradegate
19.03.26 | 21:54
77,90 Euro
+3,10 % +2,34
1-Jahres-Chart
SANOFI SA Chart 1 Jahr
5-Tage-Chart
SANOFI SA 5-Tage-Chart
RealtimeGeldBriefZeit
77,8277,9719.03.
77,8877,9119.03.

Aktuelle News zur SANOFI Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiSanofi's venglustat granted U.S. breakthrough therapy status for type 3 Gaucher disease19
MiSanofi: Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease611Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy...
► Artikel lesen
13.03.Vaxart signals $700M COVID-19 vaccine milestone path as Sanofi partnership advances and 2026 data readouts approach30
12.03.Sanofi: Information concerning the total number of voting rights and shares - February 202615
12.03.Sanofi mit Chance auf Bodenbildung: antizyklische Doppelstrategie könnte interessant sein
SANOFI Aktie jetzt für 0€ handeln
10.03.Sanofi - 6-K, Report of foreign issuer15
06.03.Sanofi strikes deal with Brazil's EMS to sell generics manufacturer Medley51
06.03.Sanofi to sell Medley unit to Brazil's EMS for more than $500M20
06.03.EMA Panel Backs Moderna's COVID-Flu Shot, Sanofi's Sleeping Sickness Drug, Ipsen's Cancer Drug826PARIS (dpa-AFX) - At its February 2026 meeting, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted positive opinions for Moderna's combined COVID-19...
► Artikel lesen
06.03.Fierce Pharma Asia-Kyowa ends OX40 program; Sanofi licenses first-in-class drug; BioNTech advances Duality ADC119
05.03.Sanofi: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director584Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director Paris, March 5, 2026. The Board of Directors of Sanofi has decided to propose, at the next...
► Artikel lesen
05.03.Sino Biopharma and Sanofi reach over $1.5 billion BD transaction51
04.03.Sanofi bets on Sino Biopharm's transplant drug in $1.5bn licensing deal30
04.03.Sanofi: Filing of an amendment to the French "Document d'Enregistrement Universel" containing the Annual Financial Report575Filing of an amendment to the French "Document d'Enregistrement Universel" containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its "Document...
► Artikel lesen
04.03.Blackstone puts $400M into Teva, Sanofi gut disease drug31
04.03.Sino Biopharm Licenses Rovadicitinib to Sanofi for up to $1.5B29
04.03.Sino Biopharm Inks USD1.5 Billion Drug Licensing Deal With Sanofi9
04.03.Sanofi bets up to $1.53B to license blood cancer drug from Sino Biopharma unit17
04.03.Teva bags $400M deal with Blackstone to fund Sanofi-partnered IBD drug13
03.03.Sanofi - 6-K, Report of foreign issuer6
Weiter >>
823 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,1,63